Cytotoxic chemotherapy for prostate cancer: Who and when?
- 1 October 2006
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 7 (5) , 370-377
Abstract
The survival benefit demonstrated by docetaxel-based therapy in two randomized trials, Southwest Oncology Group (SWOG) 99-16 and TAX 327, has changed the perception of chemotherapy in men with hormone-refractory prostate cancer from nihilism to optimism. These survival improvements are of similar magnitude to those found in trials that established chemotherapeutic regimens for metastatic breast, lung, or colorectal cancer. The timing of chemotherapy in the aforementioned solid tumors is much more clearly defined than in men with metastatic prostate cancer. Traditionally, chemotherapy in men with hormone-resistant prostate cancer was reserved for symptomatic patients only; the inclusion of symptomatic and asymptomatic patients in SWOG 99-16 and TAX 327 has raised several questions regarding the optimal use of chemotherapy in these patients. When is the best time to initiate docetaxel-based chemotherapy? Is it appropriate to use chemotherapy in high-risk patients as adjuvant therapy? Although retrospective analysis of current trials may provide hypothesis, only properly designed randomized clinical trials will answer these questions.Keywords
This publication has 31 references indexed in Scilit:
- Using prostate‐specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancerBJU International, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Chemotherapy for Hormone-Refractory Prostate Cancer: Now It's a Question of “When?”Journal of Clinical Oncology, 2005
- TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING THERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER: PATIENT REPORTED USE AND OUTCOMES FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROSTATE CANCER OUTCOMES STUDYJournal of Urology, 2005
- Approval SummaryClinical Cancer Research, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCERJournal of Urology, 2004
- Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Journal of Clinical Oncology, 2004
- Pretreatment Nomogram That Predicts 5-Year Probability of Metastasis Following Three-Dimensional Conformal Radiation Therapy for Localized Prostate CancerJournal of Clinical Oncology, 2003
- Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and PharmacokineticsJournal of Clinical Oncology, 2002